NasdaqGS:ONCBiotechs
How BeOne’s Exclusive Asian Rights to RAS(ON) Inhibitors Will Impact BeOne Medicines (ONC) Investors
Earlier in August 2026, BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a multi-part collaboration that pairs BeOne’s oncology assets with Revolution’s four clinical RAS(ON) inhibitors and grants BeOne exclusive development and commercialization rights to these agents in select Asian markets, alongside BeOne funding a global registrational Phase 3 study.
This collaboration meaningfully expands BeOne’s access to late-stage targeted cancer candidates and deepens its role in...